Abstract
In the 5 years since the first human gene therapy studies began, more than 70 clinical protocols have been approved, and over 200 patients have received genetically modified cells. A high proportion of these protocols have made use of hematopoietic progenitor cells or their mature progeny. In this review, we discuss the progress and limitations of current clinical gene transfer studies using marrow-derived progenitor cells and describe how the technique is being applied to the treatment of single-gene disorders and to augment cancer immunotherapies. We also discuss the contribution made by gene marking studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
